Literature DB >> 20460943

Primers on molecular pathways: lipopolysaccharide signaling - potential role in pancreatitis and pancreatic cancer.

Jose L Del Pozo1.   

Abstract

The innate immune system recognizes the presence of bacterial pathogens through the expression of a family of membrane receptors known as Toll-like receptors (TLRs). Lipopolysaccharide (LPS) is specifically recognized by TLR4. Recognition of microbial components by TLRs initiates signal transduction pathways, which triggers expression of genes. These gene products control innate immune responses and further instruct development of antigen-specific acquired immunity. TLR signaling pathways are finely regulated by TIR domain-containing adaptors, such as MyD88, TIRAP/Mal, TRIF and TRAM. LPS can act not only on immune cells but also on some types of epithelial cells including cancer cells and promote its transformed phenotype. Specifically, LPS can activate NF-kappaB signaling in pancreatic cancer cells, thus connecting inflammation with cancer progression. The TLR4 signaling pathway may offer a useful therapeutic target for patients with pancreatitis or pancreatic cancer associated with inflammation. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460943     DOI: 10.1159/000299987

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  10 in total

Review 1.  Mucins and toll-like receptors: kith and kin in infection and cancer.

Authors:  Shikha Tarang; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2012-02-03       Impact factor: 8.679

2.  STIM1/ORAI1-mediated Ca2+ Influx Regulates Enolase-1 Exteriorization.

Authors:  Miroslava Didiasova; Dariusz Zakrzewicz; Viktor Magdolen; Chandran Nagaraj; Zoltán Bálint; Manfred Rohde; Klaus T Preissner; Malgorzata Wygrecka
Journal:  J Biol Chem       Date:  2015-03-24       Impact factor: 5.157

Review 3.  Intervention on toll-like receptors in pancreatic cancer.

Authors:  Juan Vaz; Roland Andersson
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

4.  LPS induced miR-181a promotes pancreatic cancer cell migration via targeting PTEN and MAP2K4.

Authors:  Jianhui Liu; Dong Xu; Qingguang Wang; Datong Zheng; Xiuqin Jiang; Lijian Xu
Journal:  Dig Dis Sci       Date:  2014-02-15       Impact factor: 3.199

5.  Risk of Pancreatic Cancer in Female Textile Workers in Shanghai, China, Exposed to Metals, Solvents, Chemicals, and Endotoxin: Follow-Up to a Nested Case-Cohort Study.

Authors:  Nicholas K Reul; Wenjin Li; Lisa G Gallagher; Roberta M Ray; Megan E Romano; Daoli Gao; David B Thomas; Sverre Vedal; Harvey Checkoway
Journal:  J Occup Environ Med       Date:  2016-02       Impact factor: 2.162

6.  Inherited variation in pattern recognition receptors and cancer: dangerous liaisons?

Authors:  Anton G Kutikhin; Arseniy E Yuzhalin
Journal:  Cancer Manag Res       Date:  2012-02-16       Impact factor: 3.989

7.  Gene expression disorders of innate antibacterial signaling pathway in pancreatic cancer patients: implications for leukocyte dysfunction and tumor progression.

Authors:  Robert Słotwiński; Aleksandra Dąbrowska; Gustaw Lech; Maciej Słodkowski; Sylwia M Słotwińska
Journal:  Cent Eur J Immunol       Date:  2014-12-15       Impact factor: 2.085

Review 8.  Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer.

Authors:  Robert Słotwiński; Sylwia Małgorzata Słotwińska
Journal:  Cent Eur J Immunol       Date:  2017-01-24       Impact factor: 2.085

Review 9.  Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers.

Authors:  Chun Wai Mai; Yew Beng Kang; Mallikarjuna Rao Pichika
Journal:  Onco Targets Ther       Date:  2013-11-05       Impact factor: 4.147

Review 10.  Emerging role of Toll-like receptor 4 in hepatocellular carcinoma.

Authors:  Jing Yang; Min Li; Qi Chang Zheng
Journal:  J Hepatocell Carcinoma       Date:  2015-02-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.